Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 3Genitourinary 2Lymphoid 1

Conditions

Prostatic Neoplasms 50Neoplasm Metastasis 13Breast Neoplasms 9Carcinoma, Renal Cell 6Pain 5Osteoporosis 5Neoplasms 3Multiple Myeloma 3Kidney Neoplasms 3Lung Neoplasms 2Bone Neoplasms 2Bone Diseases, Metabolic 2Urologic Neoplasms 1Renal Insufficiency 1Insulin Resistance 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Non-Small-Cell Lung 1Bone Diseases 1

Interventions

Zoledronic Acid 2Toremifene 1Nutrition Assessment 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Diseases, Metabolic × Zoledronic Acid × Genitourinary × Clear all
NCT00063609 2017-09-13

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Novartis

Phase 4 Completed
200 enrolled
Genitourinary

Bone Diseases, Metabolic, Osteoporosis, Prostatic Neoplasms

NCT00181584 2013-07-11

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Massachusetts General Hospital

Phase 2 Completed
60 enrolled
Genitourinary

Bone Diseases, Metabolic, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡